How Canine mRNA Cancer Vaccines Work — Personalized Neoantigen Vaccines Explained
From sequencing to neoantigens to a custom formulation — how the "wanted poster" is made
A personalized canine mRNA cancer vaccine works in three steps: sequence the dog's own tumor tissue (RNA sequencing), identify the tumor's unique molecular features (neoantigens) with AI, and inject a custom mRNA-LNP formulation that teaches the immune system to recognize and attack those features. In short: it is not a drug that kills tumor cells directly — it is a "wanted poster" that trains the immune system.
Key principle: every dog's tumor is different
Two dogs with the same cancer type (say, melanoma) can have completely different mutation profiles. The meaning of "personalized" is that the poster is drawn from your dog's own tumor — it belongs to your dog alone. This is the fundamental difference from one-size-fits-all therapies.
How it works
- Sequence — fresh tumor tissue (collected during surgery) undergoes ultra-deep RNA-seq (≥50G, RIN>8.5) to detect mutations (SNVs), gene fusions, and alternative splicing — abnormal signals absent from normal cells
- Select — AI ranks candidates by immunogenicity, mutation frequency, and expression, picking 10–30 high-affinity neoantigens; a custom mRNA sequence is designed (pseudouridine-modified, 5' cap, 3' polyA tail)
- Deliver — mRNA is encapsulated in lipid nanoparticles (LNP; ionizable lipid / DSPC / cholesterol / PEG-lipid) and injected intramuscularly; the immune system learns the tumor's "face" and attacks it
Technical parameters
| Step | Parameters |
|---|---|
| Sequencing | Ultra-deep RNA-seq ≥50G, depth ≥1000× |
| Neoantigens | 10–30 high-affinity candidates selected by AI |
| Formulation | Pseudouridine-modified mRNA + 4-component LNP; QC: encapsulation rate, size, endotoxin, sterility |
| Dose | Fixed 20 µg / 0.5 mL, intramuscular (lateral thigh) |
| Schedule | 8 doses: 5 weekly priming → 14-day rest → 3 triweekly boosting |
| Timeline | ~7–9 weeks from sampling to formulation |
Why mRNA?
mRNA technology has years of clinical research in human oncology (personalized mRNA vaccines have progressed in melanoma and other indications). mRNA does not enter the nucleus, does not alter the genome, and can be rapidly customized and manufactured — canine application builds on this mature platform.
"Pseudoprogression"
In some cases, follow-up imaging may show tumors appearing larger shortly after vaccination — this can be immune cells massing at the tumor site ("pseudoprogression"), not true progression. Your veterinarian judges by imaging and clinical signs; don't abandon the protocol on a single scan.
Learn more: Study details & eligibility · Owner FAQ · Rosie case explained